JP2021527697A - ボーラス用量での経静脈メロキシカムの投与方法 - Google Patents
ボーラス用量での経静脈メロキシカムの投与方法 Download PDFInfo
- Publication number
- JP2021527697A JP2021527697A JP2020571332A JP2020571332A JP2021527697A JP 2021527697 A JP2021527697 A JP 2021527697A JP 2020571332 A JP2020571332 A JP 2020571332A JP 2020571332 A JP2020571332 A JP 2020571332A JP 2021527697 A JP2021527697 A JP 2021527697A
- Authority
- JP
- Japan
- Prior art keywords
- meloxicam
- pain
- dose
- bolus dose
- seconds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 title claims abstract description 235
- 229960001929 meloxicam Drugs 0.000 title claims abstract description 228
- 238000001990 intravenous administration Methods 0.000 title abstract description 102
- 208000002193 Pain Diseases 0.000 claims abstract description 83
- 230000036407 pain Effects 0.000 claims abstract description 76
- 238000000034 method Methods 0.000 claims abstract description 53
- 238000011282 treatment Methods 0.000 claims abstract description 51
- 238000001356 surgical procedure Methods 0.000 claims description 53
- 210000001519 tissue Anatomy 0.000 claims description 11
- 239000002159 nanocrystal Substances 0.000 claims description 10
- 238000002357 laparoscopic surgery Methods 0.000 claims description 7
- 210000004872 soft tissue Anatomy 0.000 claims description 7
- 208000004550 Postoperative Pain Diseases 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 13
- 238000009472 formulation Methods 0.000 abstract description 12
- 230000001154 acute effect Effects 0.000 abstract description 5
- 230000036592 analgesia Effects 0.000 abstract description 2
- 230000036470 plasma concentration Effects 0.000 description 25
- 238000002347 injection Methods 0.000 description 20
- 239000007924 injection Substances 0.000 description 20
- 229940068196 placebo Drugs 0.000 description 14
- 239000000902 placebo Substances 0.000 description 14
- 238000001802 infusion Methods 0.000 description 11
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 11
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 9
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 8
- 206010022086 Injection site pain Diseases 0.000 description 8
- 230000009471 action Effects 0.000 description 8
- 206010039897 Sedation Diseases 0.000 description 7
- 230000003187 abdominal effect Effects 0.000 description 7
- 208000005298 acute pain Diseases 0.000 description 7
- 230000036280 sedation Effects 0.000 description 7
- 229940083243 caldolor Drugs 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 208000004454 Hyperalgesia Diseases 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 229960001680 ibuprofen Drugs 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000002316 cosmetic surgery Methods 0.000 description 3
- 229960003964 deoxycholic acid Drugs 0.000 description 3
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 3
- 229960004752 ketorolac Drugs 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000002045 lasting effect Effects 0.000 description 3
- 229940112801 mobic Drugs 0.000 description 3
- 208000004296 neuralgia Diseases 0.000 description 3
- 229960005489 paracetamol Drugs 0.000 description 3
- 238000002271 resection Methods 0.000 description 3
- 230000000284 resting effect Effects 0.000 description 3
- 230000001624 sedative effect Effects 0.000 description 3
- -1 5-methyl-2-thiazolyl Chemical group 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 208000035154 Hyperesthesia Diseases 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 206010053552 allodynia Diseases 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000002192 cholecystectomy Methods 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002406 microsurgery Methods 0.000 description 2
- 238000002324 minimally invasive surgery Methods 0.000 description 2
- 229940051776 ofirmev Drugs 0.000 description 2
- 238000002355 open surgical procedure Methods 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010054266 Injection site discomfort Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000001294 Nociceptive Pain Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010051077 Post procedural haemorrhage Diseases 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000012084 abdominal surgery Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000001246 colloidal dispersion Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 210000004268 dentin Anatomy 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002565 electrocardiography Methods 0.000 description 1
- 238000002674 endoscopic surgery Methods 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000011471 prostatectomy Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000002432 robotic surgery Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000010206 sensitivity analysis Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011883 total knee arthroplasty Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000007879 vasectomy Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 208000009935 visceral pain Diseases 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
この出願は、2018年3月8日に出願された米国仮特許出願第62/640,232号;2018年4月4日に出願された米国仮特許出願第62/652,656号;および2018年10月23日に出願された米国仮特許出願第62/749,407号の特許法第119条(e)項に基づく利益を請求する。これらの出願は、すべての目的のため、それら全体が参照として本明細書に組み込まれる。
本開示は、静脈内ボーラス投与を含む痛みの治療のためにメロキシカムを投与する方法に関する。
本明細書において使用される専門用語は、ただ具体的な実施形態を説明する目的のためのものであり、限定を意味するものではないことが理解されるべきである。
メロキシカムの経口投与は、炎症(例えば、変形性関節症およびリウマチ性関節炎)を治療するために承認されているが、メロキシカムの現在入手可能な経口製剤は、メロキシカムの乏しい溶解性のため作用のゆっくりとした発現を示すことが知られている。経口メロキシカムの作用のゆっくりとした発現により、メロキシカムは急性の痛み管理(例えば、軽度〜中度の痛みおよび/または中度〜重度の痛み)に不適切なものとなっている。
一実施形態において、本明細書に開示されたボーラス用量は、1つまたは2つ以上の当業者に既知の薬学的に許容され得る賦形剤または担体を含むことができる。
一実施形態において、1mLの30mg/mLボーラス用量は、30mgのメロキシカムの静脈内投与後の患者において、約4000ng/mL〜約11000ng/mLの範囲の約80%〜約125%内(その間のすべての値およびサブ範囲を含む)の平均最高血漿濃度(Cmax)を提供する。すなわち、単回30mg/mLボーラス用量は、患者において約3000ng/mL、約3100ng/mL、約3200ng/mL、約3300ng/mL、約3400ng/mL、約3500ng/mL、約3600ng/mL、約3700ng/mL、約3800ng/mL、約3900ng/mL、約4000ng/mL、約4100ng/mL、約4200ng/mL、約4300ng/mL、約4400ng/mL、約4500ng/mL、約4600ng/mL、約4700ng/mL、約4800ng/mL、約4900ng/mL、約5000ng/mL、約5100ng/mL、約5200ng/mL、約5300ng/mL、約5400ng/mL、約5500ng/mL、約5600ng/mL、約5700ng/mL、約5800ng/mL、約5900ng/mL、約6000ng/mL、約6100ng/mL、約6200ng/mL、約6300ng/mL、約6400ng/mL、約6500ng/mL、約6600ng/mL、約6700ng/mL、約6800ng/mL、約6900ng/mL、約7000ng/mL、約7100ng/mL、約7200ng/mL、約7300ng/mL、約7400ng/mL、約7500ng/mL、約7600ng/mL、約7700ng/mL、約7800ng/mL、約7900ng/mL、約8000ng/mL、約8100ng/mL、約8200ng/mL、約8300ng/mL、約8400ng/mL、約8500ng/mL、約8600ng/mL、約8700ng/mL、約8800ng/mL、約8900ng/mL、約9000ng/mL、約9100ng/mL、約9200ng/mL、約9300ng/mL、約9400ng/mL、約9500ng/mL、約9600ng/mL、約9700ng/mL、約9800ng/mL、約9900ng/mL、約10000ng/mL、約10100ng/mL、約10200ng/mL、約10300ng/mL、約10400ng/mL、約10500ng/mL、約10600ng/mL、約10700ng/mL、約10800ng/mL、約10900ng/mL、約11000ng/mL、約11100ng/mL、約11200ng/mL、約11300ng/mL、約11400ng/mL、約11500ng/mL、約11600ng/mL、約11700ng/mL、約11800ng/mL、約11900ng/mL、約12000ng/mL、約12100ng/mL、約12200ng/mL、約12300ng/mL、約12400ng/mL、約12500ng/mL、約12600ng/mL、約12700ng/mL、約12800ng/mL、約12900ng/mL、約13000ng/mL、約13100ng/mL、約13200ng/mL、約13300ng/mL、約13400ng/mL、および約13500ng/mL、または上記値の間の任意の値または範囲の血漿Cmaxを提供することができる。
メロキシカム血漿濃度およびPKパラメータが観測され、Tmaxはすべての被験者で0.08時間、血漿Cmax幾何平均は5580ng/mL、そして平均t1/2は17.5時間であった(表2)。血漿AUC0-∞(時間0から無限大までの濃度−時間曲線の下の面積)幾何平均は65100hr・ng/mLであった(表2)。血漿AUC0-t(時間0から測定可能な濃度を有する最後の時点までの濃度−時間曲線の下の面積)の結果はAUC0-∞と同様であった。
Claims (20)
- 痛みの治療を必要とする患者におけるメロキシカムによる痛みの治療方法であって、(a)メロキシカムのボーラス用量を患者に静脈内投与することを含み、メロキシカムが約30mg/mLの濃度である治療方法。
- メロキシカムがメロキシカムナノ結晶として存在する請求項1記載の治療方法。
- メロキシカムのボーラス用量が約1〜約60秒にわたって患者に投与される請求項1または2記載の治療方法。
- メロキシカムの用量が約5〜約45秒にわたって患者に投与される請求項1〜3のいずれか1項に記載の治療方法。
- メロキシカムの用量が約15〜約30秒にわたって患者に投与される請求項1〜4のいずれか1項に記載の治療方法。
- メロキシカムの用量が約15mg〜約180mgの範囲にある請求項1〜5のいずれか1項に記載の治療方法。
- メロキシカムの用量が約30mgである請求項1〜6のいずれか1項に記載の治療方法。
- メロキシカムの用量が約60mgである請求項1〜6のいずれか1項に記載の治療方法。
- メロキシカムの用量が約0.5mL〜約4mLの容量で存在する請求項1〜8のいずれか1項に記載の治療方法。
- メロキシカムの用量が約1mLの容量で存在する請求項1〜9のいずれか1項に記載の治療方法。
- 痛みが手術後の痛みである請求項1〜10のいずれか1項に記載の治療方法。
- メロキシカムの用量が患者が外科手術を受けた後に投与される請求項1〜11のいずれか1項に記載の治療方法。
- 外科手術が直視下外科手術である請求項12記載の治療方法。
- 外科手術が腹腔鏡手術である請求項12記載の治療方法。
- 外科手術が硬組織に実施された請求項12記載の治療方法。
- 外科手術が軟組織に実施された請求項12記載の治療方法。
- 痛みが中度から重度の痛みである請求項1〜16のいずれか1項に記載の治療方法。
- 痛みが軽度から中度の痛みである請求項1〜16のいずれか1項に記載の治療方法。
- 段階(a)の後かつ患者が治療を必要としなくなるまで、約16時間ごと〜約26時間ごとにメロキシカムを患者に投与することをさらに含む請求項1〜18のいずれか1項に記載の治療方法。
- 段階(a)の後かつ患者が治療を必要としなくなるまで、約18時間ごと〜約24時間ごとにメロキシカムが患者に投与される請求項1〜19のいずれか1項に記載の治療方法。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862640232P | 2018-03-08 | 2018-03-08 | |
US62/640,232 | 2018-03-08 | ||
US201862652656P | 2018-04-04 | 2018-04-04 | |
US62/652,656 | 2018-04-04 | ||
US201862749407P | 2018-10-23 | 2018-10-23 | |
US62/749,407 | 2018-10-23 | ||
PCT/US2019/021354 WO2019173715A1 (en) | 2018-03-08 | 2019-03-08 | Methods of administering intravenous meloxicam in a bolus dose |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021527697A true JP2021527697A (ja) | 2021-10-14 |
JPWO2019173715A5 JPWO2019173715A5 (ja) | 2022-10-28 |
Family
ID=67842838
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020571332A Pending JP2021527697A (ja) | 2018-03-08 | 2019-03-08 | ボーラス用量での経静脈メロキシカムの投与方法 |
Country Status (7)
Country | Link |
---|---|
US (3) | US11458145B2 (ja) |
EP (1) | EP3761977A4 (ja) |
JP (1) | JP2021527697A (ja) |
KR (1) | KR20200130334A (ja) |
CN (1) | CN111201020A (ja) |
AU (1) | AU2019231858A1 (ja) |
WO (1) | WO2019173715A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3761977A4 (en) | 2018-03-08 | 2021-12-15 | Baudax Bio, Inc. | METHOD OF ADMINISTRATION OF INTRAVENOUS MELOXICAM IN A BOLUS DOSE |
CN111565713A (zh) * | 2018-11-07 | 2020-08-21 | 巴达克斯生物有限公司 | 用iv美洛昔康治疗患有血小板功能障碍的受试者的方法 |
CN115844820B (zh) * | 2022-11-23 | 2023-08-29 | 石家庄四药有限公司 | 一种美洛昔康混悬注射液及其制备方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8512727B2 (en) * | 2003-03-03 | 2013-08-20 | Alkermes Pharma Ireland Limited | Nanoparticulate meloxicam formulations |
US20100297252A1 (en) | 2003-03-03 | 2010-11-25 | Elan Pharma International Ltd. | Nanoparticulate meloxicam formulations |
DE102004030409A1 (de) * | 2004-06-23 | 2006-01-26 | Boehringer Ingelheim Vetmedica Gmbh | Neue Verwendung von Meloxicam in der Veterinärmedizin |
WO2008066899A2 (en) | 2006-11-28 | 2008-06-05 | Marinus Pharmaceuticals | Nanoparticulate formulations and methods for the making and use thereof |
HUE032426T2 (en) * | 2009-05-27 | 2017-09-28 | Alkermes Pharma Ireland Ltd | Inhibition of flake aggregation in nanoparticulate meloxicam formulations |
EP3761977A4 (en) | 2018-03-08 | 2021-12-15 | Baudax Bio, Inc. | METHOD OF ADMINISTRATION OF INTRAVENOUS MELOXICAM IN A BOLUS DOSE |
CN116327959A (zh) | 2018-05-11 | 2023-06-27 | 南京清普生物科技有限公司 | 一种美洛昔康组合物、制剂及其制备方法与应用 |
AU2019364416A1 (en) | 2018-10-23 | 2021-06-03 | Baudax Bio, Inc. | Methods of administering intravenous meloxicam pre-operatively and in combination with other drugs |
CN111565713A (zh) | 2018-11-07 | 2020-08-21 | 巴达克斯生物有限公司 | 用iv美洛昔康治疗患有血小板功能障碍的受试者的方法 |
-
2019
- 2019-03-08 EP EP19764737.3A patent/EP3761977A4/en active Pending
- 2019-03-08 AU AU2019231858A patent/AU2019231858A1/en not_active Abandoned
- 2019-03-08 JP JP2020571332A patent/JP2021527697A/ja active Pending
- 2019-03-08 CN CN201980004945.1A patent/CN111201020A/zh active Pending
- 2019-03-08 US US16/297,095 patent/US11458145B2/en active Active
- 2019-03-08 US US16/297,020 patent/US10881663B2/en active Active
- 2019-03-08 KR KR1020207027716A patent/KR20200130334A/ko not_active Application Discontinuation
- 2019-03-08 WO PCT/US2019/021354 patent/WO2019173715A1/en active Application Filing
-
2022
- 2022-08-18 US US17/820,783 patent/US20230302008A1/en active Pending
Non-Patent Citations (2)
Title |
---|
JOURNAL OF PAIN, vol. Vol.11, No.383-393, JPN6022018334, February 2018 (2018-02-01), ISSN: 0004774306 * |
POSTGRADUATE MEDICINE, vol. 129, no. 1, JPN6022018335, 2017, pages 56 - 59, ISSN: 0004965752 * |
Also Published As
Publication number | Publication date |
---|---|
US11458145B2 (en) | 2022-10-04 |
US20230302008A1 (en) | 2023-09-28 |
US10881663B2 (en) | 2021-01-05 |
AU2019231858A1 (en) | 2020-10-08 |
KR20200130334A (ko) | 2020-11-18 |
CN111201020A (zh) | 2020-05-26 |
EP3761977A1 (en) | 2021-01-13 |
US20190275054A1 (en) | 2019-09-12 |
US20190275053A1 (en) | 2019-09-12 |
US20210100811A9 (en) | 2021-04-08 |
EP3761977A4 (en) | 2021-12-15 |
WO2019173715A1 (en) | 2019-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230302008A1 (en) | Methods of administering intravenous meloxicam in a bolus dose | |
Murray et al. | Lower limb blocks | |
PT626863E (pt) | Formulacoes contendo acido hialuronico | |
US20180344855A1 (en) | Stable Anti-inflammatory Solutions for Injection | |
JP5775246B2 (ja) | 関節痛を治療する薬剤を生成するためのレシニフェラトキシン(rtx)の使用方法および前記薬剤を適用する方法 | |
KR102004021B1 (ko) | 무감각 없이 통증 경감을 위한 조성물과 방법 | |
JP2008525504A5 (ja) | ||
JP5080983B2 (ja) | バニロイド受容体アゴニストをグリコースアミノグリカンまたはプロテオグリカンとともに関節痛治療のための薬剤の製造に用いることおよび前記薬剤の適用方法 | |
JP6544818B2 (ja) | 関節疾患処置用組成物およびこれを含むキット | |
RU2426564C1 (ru) | Способ лечения асептического некроза головки бедренной кости | |
BRPI0620983B1 (pt) | Uso de derivados de triazina para fabricação de um medicamento, e composição farmacêutica para uso tópico | |
JP2008143856A (ja) | 非ステロイド系抗炎症剤配合医薬 | |
ES2630102T3 (es) | Oximetazolina para el tratamiento de trastornos ano-rectales | |
RU2454935C2 (ru) | Способ парапанкреатических блокад | |
BRPI0708386A2 (pt) | método de preparação para composição estável moderna que inclui aceclofenac e 2,5-di-o-metil-1,4:3,6-dianhydro-d-glucitol como solvente e método de seu uso | |
KR20210081354A (ko) | 멜록시캄(meloxicam)을 수술 전에 다른 약물과 함께 정맥내 투여하는 방법 | |
Kartal et al. | Nicolau syndrome: a rare complication of injection that should be kept in mind | |
CN101208095A (zh) | 瑞波西汀在治疗疼痛中的应用 | |
WO2018168921A1 (ja) | 関節疾患処置用組成物およびこれを含むキット | |
AU2012244095A1 (en) | Method for the non-surgical treatment of lipodystrophy in a retrovirus-infected individual | |
Ansari et al. | An Observational Study Comparing Hybrid Transvaginal Notes and Four-Port Laparoscopic Cholecystectomy | |
Swaminathan | Comparative Evaluation of Transdermal Diclofenac and Oral Diclofenac in Management of Post Operative Pain in Bilateral Extractions: An In Vivo study | |
UA122476C2 (uk) | М'яка лікарська форма для місцевого лікування поверхневих інфантильних гемангіом | |
UA146634U (uk) | Спосіб профілактики внутрішньочеревної гіпертензії |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210409 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210409 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220517 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220817 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20221017 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230117 |